G2 Phase Cell Cycle Checkpoints
"G2 Phase Cell Cycle Checkpoints" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CELL CYCLE regulatory signaling systems that are triggered by DNA DAMAGE or lack of nutrients during G2 PHASE. When triggered they restrain cells transitioning from G2 phase to M PHASE.
| Descriptor ID |
D059565
|
| MeSH Number(s) |
G04.144.109.500 G04.144.500.340.500
|
| Concept/Terms |
G2 Phase Cell Cycle Checkpoints- G2 Phase Cell Cycle Checkpoints
- G2 Phase Checkpoints
- Checkpoint, G2 Phase
- Checkpoints, G2 Phase
- G2 Phase Checkpoint
- G2 Cell Cycle Checkpoints
G2 Restriction Point- G2 Restriction Point
- G2 Restriction Points
- Restriction Point, G2
- Restriction Points, G2
Antephase Checkpoint- Antephase Checkpoint
- Antephase Checkpoints
- Checkpoint, Antephase
- Checkpoints, Antephase
|
Below are MeSH descriptors whose meaning is more general than "G2 Phase Cell Cycle Checkpoints".
Below are MeSH descriptors whose meaning is more specific than "G2 Phase Cell Cycle Checkpoints".
This graph shows the total number of publications written about "G2 Phase Cell Cycle Checkpoints" by people in this website by year, and whether "G2 Phase Cell Cycle Checkpoints" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "G2 Phase Cell Cycle Checkpoints" by people in Profiles.
-
Pai HC, Kumar S, Shen CC, Liou JP, Pan SL, Teng CM. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27. PLoS One. 2015; 10(4):e0123819.
-
Tsai AC, Pai HC, Wang CY, Liou JP, Teng CM, Wang JC, Pan SL. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells. Br J Pharmacol. 2014 Jan; 171(1):122-33.